SRC and polycystic kidney disease: While interventions targeting a number of these pathways have demonstrated promise in preclinical models of polycystic kidney disease, only the Src/Bcr-Abl inhibitor bosutinib and the multi-kinase inhibitor tesevatinib have thus far progressed into randomised clinical trials (Zhou and Torres, 2023).